Overview

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Status:
Completed

Trial end date:
2018-03-19

Target enrollment:
0

Participant gender:
All

Summary

The primary objectives of this study are to determine the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection with or without cirrhosis, who did not achieve sustained viral response (SVR) after receiving prior treatment in a Gilead-sponsored HCV treatment study of direct-acting antiviral (DAA)-containing regimens.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir
Velpatasvir

Criteria

Key Inclusion Criteria:

- Chronically HCV-infected males and non-pregnant/non-lactating females aged 18 years or
older who did not achieve sustained virologic response (SVR) in a prior
Gilead-sponsored HCV treatment study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.